Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency by Mohammad Al-Ansari & James D. Craik
Al-Ansari and Craik BMC Hematology  (2015) 15:17 
DOI 10.1186/s12878-015-0038-0RESEARCH ARTICLE Open AccessDecreased erythrocyte nucleoside transport
and hENT1 transporter expression in
glucose 6-phosphate dehydrogenase
deficiency
Mohammad Al-Ansari and James D. Craik*Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with erythrocyte sensitivity to
oxidative damage and hemolytic crises. In β-thalassemia major, where hemoglobin instability imposes oxidative
stress, erythrocytes show reduced hENT1 nucleoside transporter expression and decreased nucleoside uptake. This
study investigated hENT1 expression and nucleoside transport in G6PD-deficient erythrocytes to determine if
decreased hENT1 activity might be a contributory feature in the variable pathology of this enzymopathy.
Methods: Uptake of 3H-uridine was measured at room temperature using an inhibitor-oil stop protocol and 5-s
incubations. Erythrocyte membranes were analyzed by SDS-PAGE and nucleoside (hENT1), glucose (GLUT-1), and
anion exchange (Band 3) transporter polypeptides quantitated on immunoblots.
Results: In G6PD-deficient cells, uridine uptake (mean 8.18, 95 % CI 5.6–10.7 vs controls mean 12.35, 95 % CI 9.2–15.5,
pmol uridine/gHb/min; P = 0.031) and expression of hENT1 (mean 50.4 %, 95 % CI 38.1–62.7 %, arbitrary units n = 11 vs
controls mean 95.23 %, 95 % CI 88.38–102.1 % arbitrary units, n = 8; P < 0.001) were significantly lower; expression of
GLUT-1 (mean 106.9 %, vs control mean 99.75 %; P = 0.308) and Band 3 polypeptides (mean 100.1 %, vs control mean
102.84 %; P = 0.329) were unchanged.
Conclusions: Nucleoside transporter activity in human erythrocytes sustains intracellular purine nucleotide levels and
assists in control of plasma adenosine levels; decreased hENT1 expression and activity in G6PD-deficiency could affect
red metabolism and influence a wide spectrum of responses mediated by adenosine receptors.
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Glucose-6-phosphate dehydrogenase (G6PD) deficiency is
one of the most common inherited metabolic disorders in
humans with highest frequencies found in African, South
Asian, Middle Eastern and Mediterranean populations
[1, 2]. Over 140 different mutations leading to G6PD
deficiency have been reported, most of which are single
base changes leading to amino acid substitutions [3, 4].
The WHO has grouped G6PD variants into classes
(Classes I to V) based upon residual enzyme activity; each
class incorporates a number of genotypes and this genetic* Correspondence: james@hsc.edu.kw
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ual clinical presentation of subjects within a single pheno-
typic class. Association of high population frequencies of
G6PD deficiency with geographical distribution of areas
where malaria has been endemic suggested that these
genetic variations might confer advantages with respect to
resistance to malaria, a conjecture that gave rise to
‘Haldane’s malaria hypothesis’ in which the selective pres-
sures from the disease drive hematological polymorphism
in affected populations [5]. This has proved a valuable
framework for understanding the presence of a very high
frequency of G6PD mutations in different human popula-
tions and suggested potential molecular mechanisms for
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consequences of genetic variations are readily observed
in males. Heterozygous females are genetic mosaics
resulting from random X chromosome inactivation
(‘Lyonization’) and thus both normal and G6PD-deficient
erythrocytes can be observed in their circulation [8, 9].
However, it has not been easy to demonstrate clear het-
erozygote advantage of G6PD-deficiency in population
studies [10, 11].
Glucose-6-phosphate dehydrogenase catalyzes the first
and rate-limiting step of the pentose phosphate catabolic
pathway which, in mature human erythrocytes, serves as
the sole metabolic source of NADPH; this provides the
reducing equivalents required to protect the cell from
oxidation-induced injury through activity of the glutathi-
one system [12, 13]. Deficiency of G6PD activity renders
a red cell highly susceptible to oxidative damage; a
clinical consequence of this can be hemolytic anemia.
Severity of disease is highly variable and hemolytic crises
in G6PD-deficient individuals may be triggered by a var-
iety of oxidative stimuli including certain foods (favism),
pharmaceuticals (particularly antimalarial drugs, such as
primaquine, and sulphonamide anti-bacterial drugs) and
infections [2, 7, 8, 12]. Although all individuals suffering
from favism appear to show G6PD-deficiency, not all
G6PD-deficient individuals suffer from favism; this has
led to speculation that other inherited factor(s) in
addition to G6PD genotype differences present within
broadly defined phenotypic classes may be important in
determining the pathological problems associated with
this enzymopathy [14, 15].
The human erythrocyte is unable to synthesize purine
nucleotides de novo and therefore these cells rely upon
exogenous purines, predominantly purine nucleosides,
to maintain levels of adenine nucleotides required for
red cell energy metabolism [16, 17]. Because of their size
and polarity, physiological nucleosides traverse biological
membranes very slowly by passive diffusion. Most
human cells, including erythrocytes, express nucleoside
transporter polypeptides in the plasma membrane to
catalyze rapid nucleoside permeation [18]. In the human
erythrocyte, rapid transmembrane fluxes of nucleosides
are mediated by an equilibrative transporter, hENT1,
which shows acute sensitivity towards reversible in-
hibition by nanomolar concentrations of nitroben-
zylthioinosine (often abbreviated to NBMPR or NBTI)
and related compounds [19, 20]. Recently it has been
reported that hENT1 is also an effective mediator of
red cell hypoxanthine transport [21]. The contribution
of purine nucleosides (principally inosine secreted by
the liver) to erythrocyte metabolism is well estab-
lished [22, 23] and their significance under different
conditions may be explored through numerical ana-
lysis of metabolic networks (for example [24]).Nucleoside transport in erythrocytes is readily inhib-
ited by treatment of cells with diamide [25] suggesting
that the transporter is highly sensitive to membrane
effects of oxidative stress. Gero and co-workers [26]
reported that red cells from patients in Myanmar with
G6PD-deficiency showed depressed adenosine uptake, a
finding consistent with impaired nucleoside transporter
activity. Erythrocytes from Kuwaiti patients diagnosed
with beta-thalassemia major, a hemoglobinopathy that
imposes oxidative stress in red cells, show decreased
nucleoside transport activity and this decrease was
associated with a substantial reduction in erythrocyte
expression of hENT1 [27]. However, these cells did not
show decreased membrane expression of another im-
portant nutrient transporter, the equilibrative glucose
transporter, GLUT1.
This study investigated hENT1 expression and nucleo-
side transport activity in erythrocytes with G6PD defi-
ciency to determine if changes in nucleoside transporter
expression and activity might be a contributory feature
of the variable pathology of erythrocytes demonstrating
this common enzymopathy and thus represent a param-
eter of clinical interest.
Methods
Materials
Phosphate buffered saline (PBS) was prepared as 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.76 mM KH2PO4,
pH 7.4. Electroblotting transfer buffer was prepared as
25 mM Tris, 192 mM glycine pH 8.3, 5 % (v/v) methanol.
Radiotracer uridine [5,6-3H], 37 Ci/mmol was from MP
Biomedical, USA. Protease inhibitors; phenylmethylsulfo-
nyl fluoride (PMSF) and protease inhibitor cocktail; Sigma
product P2714, were from Sigma Chemical Co, USA.
Dilazep was a generous donation from Hoffman-La Roche
Ltd, Canada. Rabbit antiserum directed against GLUT-1
polypeptides (C-terminal epitope) was from Alpha
Diagnostics, San Antonio, TX, USA. Murine monoclonal
IgG specific for human Band 3 polypeptides (B9277; clone
BIII-136 directed against N-terminal cytoplasmic epitope)
was from Sigma Chemical Co, USA. Murine monoclonal
antibody specific for hENT1 (10D7G2) was a gift from
Professor Carol Cass, Department of Oncology, University
of Alberta, Canada.
Subjects and samples
Blood samples (2 ml to 5 ml volumes in heparin or acid
citrate dextrose anticoagulant) were obtained with written
informed consent, mostly as surplus from samples used
for routine hematological monitoring of patients with a
laboratory demonstration of G6PD-deficiency. Individuals
taking medication(s), or with any indication of recent
hemolytic crisis or blood transfusion were excluded from
the study; twenty one samples were analyzed. Quantitative
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used RANDOX G-6-PDH kit and LXI725 Beckman
Coulter analyzer using values for G6PD deficiency set by
the Kuwait Ministry of Health (reference range 70–
180 mU per 109 cells); less than 70 mU per 109 cells was
considered to be G6PD-deficient. The average value for
the study group was 24.47 mU with range from 5.6–
51.5 mU (WHO Class III deficiency). Samples were
cooled on ice immediately after collection (Sabah or
Mubarak Al-Kabeer Hospitals, Kuwait) and processed
within 48 h of collection. Control samples were ob-
tained with written informed consent from blood do-
nors attending the Central Blood Bank, Jabriya,
Kuwait; control subjects were of Arab ethnicity,
mostly of Kuwaiti nationality. Ethical approval for the
study was granted by the Ethics Committee, Faculty of
Medicine, Kuwait University.Processing of blood samples
Blood samples were subjected to centrifugation (500 × g,
5 min) to remove plasma proteins, platelets, and white
blood cells. Following centrifugation, the red cell fraction
was washed twice (resuspension in PBS and centrifuga-
tion, 500 × g, 5 min) to give an erythrocyte preparation
depleted of extracellular medium and plasma proteins.
For uridine uptake measurements, cell suspensions of
about 30 % hematocrit in PBS were prepared. Erythro-
cyte counts of cell suspensions were performed manually
using a hemocytometer (Hycor, Fisher Scientific, UK).
Hemoglobin was determined spectroscopically after lysis
of red cells in Drabkin reagent; reticulocyte counts were
obtained by use of an automated hematological analyzer
(Beckman Coulter GEN-S, USA).Red cell membrane preparation
Red cell membranes were prepared by a conventional
hypotonic cell lysis protocol [27]. Briefly, washed eryth-
rocytes (above) were lysed in 20–50 volumes of ice-cold
buffer (5 mM phosphate, pH 8.0) in the presence of
0.1 mM phenylmethylsulfonyl fluoride (PMSF) and a
commercial cocktail of protease inhibitors; the cocktail
was diluted (50 μl/100 ml) in lysis medium and PMSF
added immediately prior to addition of erythrocytes.
Membranes were collected by high-speed centrifugation
(15 min, ≈ 26,000 × g) and the supernatant fluid discarded.
Membranes were washed by repeated (usually 5–6 times)
resuspension and centrifugation until an off-white mem-
brane preparation was obtained. Protein concentrations
were estimated by the Lowry method [28] in the presence
of sodium dodecyl sulfate using bovine serum albumin as
a standard. Membranes were stored as small aliquots in
5 mM phosphate, pH 8.0 at −80 °C prior to electrophor-
etic analysis.Assay of uridine transport in human erythrocytes
Uptake of 3H-uridine for short time periods at room
temperature was measured using a conventional ‘inhibi-
tor-oil stop’ protocol [27]. Briefly, 50 μl portions of
silicone oil mixture (density 1.034 g/ml; Dow Corning
550 and 200/1c mixed in a ratio of 86:14) were placed in
1.5 ml microcentrifuge tubes and 50 μl portions of
erythrocyte suspension (~30 % hematocrit) introduced
as a single drop upon the oil layer. Uridine radiotracer
solution in PBS containing 3H-uridine radiotracer at a
concentration of 2 μCi/ml was prepared. Transport was
initiated by rapid addition of uridine tracer solution and
terminated after a precise interval by rapid addition of
500 μl ice-cold ‘stopper’ solution (40 μM dilazep in PBS)
followed by immediate centrifugation (Eppendorf centri-
fuge 54215C, full speed ≈ 14,000 × g) for 1 min to gener-
ate a red cell pellet separated by a layer of silicone oil
from supernatant fluid. Supernatant fluid was carefully
removed and the tube above the oil layer washed by
careful addition and removal of about 1 ml distilled
water. After removal of oil, the erythrocyte pellet was
disrupted by addition of 200 μl 0.5 % (v/v) Triton X-100
in distilled water and vortex mixing. Protein was precipi-
tated by addition of 200 μl of 5 % (w/v) trichloroacetic
acid and brief vortex mixing and the precipitate pelleted
by centrifugation (full speed, 4 min). A 300 μl portion of
the supernatant was mixed with 3 ml scintillation fluid
(Aquasol-2, Beckman Instruments, USA) and radioactivity
determined using a Beckman LS 6000TA scintillation
counter. Radioactivity associated with extracellular
medium trapped in the erythrocyte pellet was estimated
from tubes in which ‘stopper’ solution was added immedi-
ately prior to uridine tracer addition or the addition of
erythrocyte suspension to a mixture of uridine and stop-
per solution. Uptake of uridine after 5 s of incubation was
determined as the mean of quadruplicate measurements.
Hemoglobin concentrations in hemolysates were deter-
mined using Drabkin reagent and measurement of absorb-
ance at 540 nm.
Electrophoretic analysis and immunoblot protocols
Membrane proteins were analyzed by SDS-PAGE (Bio
Rad Mini-gel system according to protocols provided by
BioRad, USA; 10 % polyacrylamide gel, 4 % stacking
gel, Laemmli discontinuous buffer system, 200v) after
solubilization of proteins in sample buffer in the pres-
ence of β-mercaptoethanol as reported previously
[27]. For each analysis, quadruplicate gels were pre-
pared with two being used for SDS-PAGE analysis
and two for immunoblots. Proteins were transferred
to polyvinylidine difluoride (PVDF) membranes (0.45
micron pore size, Millipore Immobilon-P, Millipore,
USA or BioRad, USA) overnight at 30 V in a cold
room (6–8 °C) using Towbin transfer buffer with 5 %
Fig. 1 Immunoblot showing protein expression in control and G6PD-
deficient erythrocytes: Comparison of erythrocyte membranes from
control and G6PD-deficient individuals. Images of an immunoblot
probed with antibodies specific for hENT1 (panel a) then stripped and
re-probed with antibodies directed against GLUT1 polypeptides
(panel b) before stripping and re-probing for AE-1 (Band 3) polypeptides
(panel c). Control membrane preparation (24, 12, 6 and 3 μg membrane
protein); membranes from G6PDH-deficient individual (duplicate lanes
of 24 and 12 μg membrane protein)
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Coomassie blue R-250 (0.25 % w/v in 50 % v/v
methanol, 10 % v/v acetic acid) and destained (5 % v/v
methanol, 7.5 % v/v acetic acid) prior to scanning densi-
tometry (Syngen Bioimaging Systems).
After electrophoretic transfer of proteins (confirmed
by reversible staining with Ponceau S in 1 % acetic acid
and washing with PBS), blots were allowed to dry at
room temperature. Protocols for antigen detection and
quantitation followed those described previously [27]
using blocking solutions of 5 % non-fat milk powder dis-
solved in 0.2 % (v/v) Tween-20 in PBS. Incubations with
primary antibodies were at ≈ 6 °C for 6–18 h with gentle
agitation; incubations with secondary antibodies were
for 2–4 h. Experimental controls from which the pri-
mary antibodies were omitted showed no staining in
pertinent regions of the blot (data not shown). Proteins
were detected by probing blots first with a murine
monoclonal antibody specific for hENT1 (antibody
10D7G2; [29]) followed by horseradish peroxidase-
conjugated second antibodies and commercial chemilu-
minescence detection systems (ECL plus, RPN1232 and
ECL, RPM 2108 kits, Amersham Biosciences, UK) and
Biomax Light Chemiluminescence film (Kodak, USA).
Film was developed manually and band densities quanti-
tated using a densitometry analysis system (Syngene
Chemi Genius Bio Imaging System). Blots were subse-
quently stripped (5 mM Tris pH 6.8, 2 % SDS, 100 mM
β-mercaptoethanol in deionized H2O) at 50 °C for
20 min with agitation at 5-min intervals. Membranes
were washed twice for 10 min in PBS at room
temperature before blocking and re-probing for GLUT-1
glucose transporter polypeptides. Blots were then sub-
jected to a further round of stripping and blocking to
detect and quantify Band 3 (also termed AE1) polypep-
tides. The level of target protein (hENT1, GLUT1, AE1)
was compared to dilutions of a standard membrane
preparation (a red cell membrane preparation from a
single normal donor stored in small aliquots at −80 °C)
present on the same blot. Multiple film exposures were
taken from each blot to ensure that for quantitative
analysis the densities of unknowns fell within the range
of densities of different amounts of standard membrane
preparation transferred on the same blot.
Data analysis
Two identical replicate blots were prepared and analyzed
for each membrane sample (from G6PD-deficient or
control individuals). Results of replicate blots were
averaged and the average values used for subsequent
analysis. Tests of distribution curves were performed;
these supported application of non-parametric tests to
investigate changes in membrane transporter (hENT1)
expression between G6PDH-deficient patients andcontrols. Statistical analysis was performed using SPSS
and Graphpad Prism software. P values below 0.05 were
taken to be significant.
Results
No consistent qualitative differences in the protein pro-
files between GD6PD-deficient and control erythrocyte
membranes were observed in SDS-PAGE gels stained with
Coomassie blue (data not shown). However, decreased
levels of hENT1 in G6PD-deficient cells were apparent
from immunoblots (Figs. 1 and 2). Decrease in expression
of hENT1 was significant (mean 50.4 %, 95 % CI
38.1–62.7 %, n = 11 P < 0.001 vs controls mean
95.2 %, 95 % CI 88.4–102.1 % n = 8; arbitrary units)
and was paralleled by a finding of significantly lower
uridine uptake in G6PD-deficient cells than in normal
erythrocytes (mean 8.18, 95 % CI 5.6–10.7 pmol uridine/g
Hb/min compared to mean 12.35, 95 % CI 9.2–15.5 pmol
uridine/g Hb/min; P = 0.031) Fig. 3. Expression of GLUT-
1 (Fig. 3; mean 106.9 %, 95 % CI 96.7–117.1 % n = 11 vs
control mean 99.8 %, 95 % CI 91.4–108.1 % n = 8; arbi-
trary units) and Band 3 polypeptides (mean 100.1 %, 95 %
CI 97.2–102.8 % n = 11 vs control mean 102.84 %, 95 % CI
95.72–109.96 % n = 8) were not significantly different with
P values of 0.308 and 0.329, respectively.
Discussion
This study shows that erythrocytes from individuals with
G6PD-deficiency have lower amounts of hENT1 nucleoside
Fig. 2 Expression of nucleoside transporter polypeptides and uridine transport rates in G6PD-deficient and control subjects: Expression and activity of
nucleoside transporter hENT1 in G6PD-deficient and control subjects. Panel a shows hENT-1 protein expression estimated from immunoblots;
transporter expression from both G6PDH-deficient patients and control subjects normalized to total membrane protein were compared to a
common standard membrane preparation (arbitrarily set to 100 %, vertical axis). Panel b shows comparison of initial rates of uridine flux into
washed erythrocytes at room temperature
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lower nucleoside transport activity. This is not a general
change in red cell membrane protein composition since the
glucose transporter GLUT1 and anion exchanger AE1 poly-
peptides are not appreciably affected. Decrease in expres-
sion of hENT1 showed substantial variation between
different individuals with G6PD deficiency. Participants in
the study were not genotyped; however, previous reportsFig. 3 Expression levels of glucose transporter GLUT1 and anion exchange
patients and control subjects: Expression levels of glucose transporter GLUT
from G6PDH-deficient patients and control subjects. Panel a shows levels of G
polypeptides. Transporter polypeptide expression was normalized to total me
control subjects were compared to a common standard membrane preparat[30, 31] and review of the patient notes suggest that the
majority of our study population would be G6PD Mediter-
ranean. G6PD genotype could be a significant factor for
hENT1 expression and thus contribute to the variation ob-
served within our G6PD-deficient group. The current study
did not furnish evidence regarding the mechanism(s) re-
sponsible for the decrease in hENT1 levels; we would
speculate that likely possibilities would include decreasedr AE-1 polypeptides in erythrocyte membranes from G6PDH-deficient
1 and anion exchanger AE-1 polypeptides in erythrocyte membranes
LUT1 glucose transporter and (Panel b) anion exchanger AE-1 (Band 3)
mbrane protein and samples from both G6PDH-deficient patients and
ion (arbitrarily set to 100 %, vertical axis)
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mental sequence or alteration in protein sorting
resulting in vesicular loss of hENT1 along with com-
ponents such as the transferrin receptor when the
membrane is remodeled late in cell maturation. We
hope to address this question, and potential role of
genotype differences, in future investigations.
In G6PD-deficiency, reduced expression of hENT1 in
the erythrocyte will lead to lower transmembrane purine
fluxes; these lower fluxes will be further curtailed by de-
creased transporter activity under conditions of oxidative
stress. This would be expected to have effects on red cell
metabolism and stability, and on clearance of adenosine
from the plasma which could influence local extracellu-
lar adenosine concentrations.
The red cell utilizes extracellular purines both to
maintain its intracellular purine nucleotide pool and,
through the action of purine nucleoside phosphorylase,
may exploit the pentose moiety for energy production. It
is tempting to speculate that decreased purine transport
could be of significance in malaria infection since it has
been established that the intraerythrocytic malaria para-
site is dependent on host cell purines, and the extracel-
lular milieu, for a supply of purines to support metabolic
activity and cellular development [32]. Following inva-
sion, the parasite inserts polypeptides into the host
erythrocyte membrane that modify solute permeation;
however, even after these changes, it is believed that the
parasite still relies upon hENT1 present in the host cell
membrane to mediate purine nucleoside entry essen-
tial for parasite development [33]. Intracellular oxida-
tive stress in erythrocytes is a general characteristic of
the most prominent inherited hemoglobinopathies
(thalassemias, sickle cell disease) and enzymopathy
(G6PD-deficiency) present in human populations sub-
jected to endemic malaria; in vitro studies have dem-
onstrated that the parasite is intolerant of oxidative
stress [34]. As noted previously, nucleoside transport
activity of ENT1 in red cells is readily inhibited by
oxidant treatment of cells in vitro [25]. It is possible
that a combination of oxidative stress and limited
purine availability could produce a synergistic effect
in slowing parasite growth and replication within the
host cell thus increasing the chances of recognition,
sequestration and destruction of an infected cell be-
fore merozoite release.
We might also surmise that variation in hENT1 expres-
sion in G6PD deficiency could produce a spectrum of
metabolic constraint that could contribute to differential
susceptibility to favism and/or drug sensitivity between
different individuals with G6PD-deficiency. This hypothesis
predicts a positive association between lower erythro-
cyte hENT1 expression and likelihood and severity of
favism or drug sensitivity in different individualsshowing similar G6PD-deficiency phenotypes. Changes to
plasma adenosine levels may also influence erythrocyte
metabolism and stability as demonstrated in recent inves-
tigations of sickle cell disease [35].
Conclusions
Expression of hENT1 in erythrocytes is significantly
decreased in G6PD-deficiency and this deficiency is associ-
ated with lower nucleoside permeation rates. Concordance
of changes in hENT1 expression and nucleoside transport
indicates that in the absence of complicating factors, such
as infection or exogenous oxidative stress, the principal
cause of changes to nucleoside flux rates is expression of
transporter rather than changes to functional properties of
the transporter in the plasma membrane.
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